



## INDIAN PHARMACOPOEIA COMMISSION

National Coordination Centre- Pharmacovigilance Programme of India (PvPI)

MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA

SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.

Tel No: 0120- 2783392, 2783400, 2783401, Fax: 0120-2783311

e-mail: pvpi.ipc@gov.in, ipclab@vsnl.net, Web: www.ipc.gov.in

File No. IPC/NCC-PvPI/DSA/2017-18/09

September 2017

### Drug Safety Alerts

The preliminary analysis of ADRs from the PvPI database reveals that the following drugs are associated with the risks as given below.

Table

Sl. No	Suspected Drugs	Indication	Adverse Reactions
1	Acetazolamide	Adjunct in treatment of chronic open-angle glaucoma; secondary glaucoma; as a part of pre-operative treatment of acute angle-closure glaucoma	Drug Hypersensitivity Syndrome
2	Linagliptin	Type 2 Diabetes Mellitus	Acute Generalised Exanthematous Pustulosis (AGEP)
3	Diloxanide	Amoebiasis	Glossitis

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above adverse events associated with the use of above drugs. If such events are encountered please report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/ Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>) or by PvPI Helpline No. **1800-180-3024**.